245 related articles for article (PubMed ID: 32870995)
21. Clinical implementation and current advancement of blood liquid biopsy in cancer.
Watanabe K; Nakamura Y; Low SK
J Hum Genet; 2021 Sep; 66(9):909-926. PubMed ID: 34088974
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
23. The potential of ctDNA analysis in breast cancer.
Tzanikou E; Lianidou E
Crit Rev Clin Lab Sci; 2020 Jan; 57(1):54-72. PubMed ID: 31674269
[TBL] [Abstract][Full Text] [Related]
24. Genetic profiling of cancer with circulating tumor DNA analysis.
Lu L; Bi J; Bao L
J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
[TBL] [Abstract][Full Text] [Related]
25. Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows.
Lampignano R; Neumann MHD; Weber S; Kloten V; Herdean A; Voss T; Groelz D; Babayan A; Tibbesma M; Schlumpberger M; Chemi F; Rothwell DG; Wikman H; Galizzi JP; Riise Bergheim I; Russnes H; Mussolin B; Bonin S; Voigt C; Musa H; Pinzani P; Lianidou E; Brady G; Speicher MR; Pantel K; Betsou F; Schuuring E; Kubista M; Ammerlaan W; Sprenger-Haussels M; Schlange T; Heitzer E
Clin Chem; 2020 Jan; 66(1):149-160. PubMed ID: 31628139
[TBL] [Abstract][Full Text] [Related]
26. From Somatic Variants Toward Precision Oncology: An Investigation of Reporting Practice for Next-Generation Sequencing-Based Circulating Tumor DNA Analysis.
Peng R; Zhang R; Horan MP; Zhou L; Chai SY; Pillay N; Tay KH; Badrick T; Li J
Oncologist; 2020 Mar; 25(3):218-228. PubMed ID: 32162803
[TBL] [Abstract][Full Text] [Related]
27. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond.
Keller L; Belloum Y; Wikman H; Pantel K
Br J Cancer; 2021 Jan; 124(2):345-358. PubMed ID: 32968207
[TBL] [Abstract][Full Text] [Related]
28. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
Abbosh C; Birkbak NJ; Swanton C
Nat Rev Clin Oncol; 2018 Sep; 15(9):577-586. PubMed ID: 29968853
[TBL] [Abstract][Full Text] [Related]
29. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
30. Liquid biopsy: unlocking the potentials of cell-free DNA.
Chu D; Park BH
Virchows Arch; 2017 Aug; 471(2):147-154. PubMed ID: 28466157
[TBL] [Abstract][Full Text] [Related]
31. Pre-analytical factors affecting the establishment of a single tube assay for multiparameter liquid biopsy detection in melanoma patients.
Schneegans S; Lück L; Besler K; Bluhm L; Stadler JC; Staub J; Greinert R; Volkmer B; Kubista M; Gebhardt C; Sartori A; Irwin D; Serkkola E; Af Hällström T; Lianidou E; Sprenger-Haussels M; Hussong M; Mohr P; Schneider SW; Shaffer J; Pantel K; Wikman H
Mol Oncol; 2020 May; 14(5):1001-1015. PubMed ID: 32246814
[TBL] [Abstract][Full Text] [Related]
32. Liquid biopsy enters the clinic - implementation issues and future challenges.
Ignatiadis M; Sledge GW; Jeffrey SS
Nat Rev Clin Oncol; 2021 May; 18(5):297-312. PubMed ID: 33473219
[TBL] [Abstract][Full Text] [Related]
33. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.
Krug AK; Enderle D; Karlovich C; Priewasser T; Bentink S; Spiel A; Brinkmann K; Emenegger J; Grimm DG; Castellanos-Rizaldos E; Goldman JW; Sequist LV; Soria JC; Camidge DR; Gadgeel SM; Wakelee HA; Raponi M; Noerholm M; Skog J
Ann Oncol; 2018 Mar; 29(3):700-706. PubMed ID: 29216356
[TBL] [Abstract][Full Text] [Related]
34. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
[TBL] [Abstract][Full Text] [Related]
35. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.
Osumi H; Shinozaki E; Takeda Y; Wakatsuki T; Ichimura T; Saiura A; Yamaguchi K; Takahashi S; Noda T; Zembutsu H
Cancer Med; 2019 Jan; 8(1):408-417. PubMed ID: 30575318
[TBL] [Abstract][Full Text] [Related]
36. Bioinformatics Analysis for Cell-Free Tumor DNA Sequencing Data.
Chen S; Liu M; Zhou Y
Methods Mol Biol; 2018; 1754():67-95. PubMed ID: 29536438
[TBL] [Abstract][Full Text] [Related]
37. The cornerstone of integrating circulating tumor DNA into cancer management.
Li Z; Yi L; Gao P; Zhang R; Li J
Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):1-11. PubMed ID: 30419316
[TBL] [Abstract][Full Text] [Related]
38. Circulating tumor DNA tracking through driver mutations as a liquid biopsy-based biomarker for uveal melanoma.
Bustamante P; Tsering T; Coblentz J; Mastromonaco C; Abdouh M; Fonseca C; Proença RP; Blanchard N; Dugé CL; Andujar RAS; Youhnovska E; Burnier MN; Callejo SA; Burnier JV
J Exp Clin Cancer Res; 2021 Jun; 40(1):196. PubMed ID: 34134723
[TBL] [Abstract][Full Text] [Related]
39. A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR.
Cavallone L; Aldamry M; Lafleur J; Lan C; Gonzalez Ginestet P; Alirezaie N; Ferrario C; Aguilar-Mahecha A; Basik M
Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):909-916. PubMed ID: 30824523
[TBL] [Abstract][Full Text] [Related]
40. Using Liquid Biopsy in the Treatment of Patient with OS.
Shulman DS; Crompton BD
Adv Exp Med Biol; 2020; 1257():95-105. PubMed ID: 32483734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
